Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Capecitabine, and Temozolomide for Pancreatic NETs
NCT01525082Phase 2Completed
- Start
- Dec 2012
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Pancreatic neuroendocrine tumor (PanNET). Started Dec 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01525082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01525082.